Humoral response to cancer as a tool for biomarker discovery

Journal of Proteomics

Volumn 72, Issue 6, 2009, Pages 982-988

  Desmetz, C ^a,b,c   Cortijo, C ^b   Mange A ^a,b,c   Solassol, J ^a,b,c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Autoantibodies; Cancer; Proteomics; Serum marker; Tumour associated antigen

Indexed keywords

COMPLEMENTARY DNA;

ARTICLE; BREAST CANCER; DISEASE MARKER; FUNCTIONAL PROTEOMICS; HUMAN; HUMORAL IMMUNITY; NEOPLASM; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MICROARRAY; SEROLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIBODY FORMATION; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD PROTEINS; DNA, COMPLEMENTARY; GENE LIBRARY; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEOME; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 67651215701     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2009.06.004     Document Type: Article

References (43)

1. Baldwin R.W. Tumour-specific immunity against spontaneous rat tumours. Int J Cancer 1 (1966) 257-264
2. Baldwin R.W. An immunological approach to cancer. Lav Ist Anat Istol Patol Univ Studi Perugia 28 (1968) 65-85
3. Baldwin R.W. Tumour-associated antigens and tumour-host interactions. Proc R Soc Med 64 (1971) 1039-1042
4. Anderson K.S. LaBaer J.: the sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4 (2005) 1123-1133
5. Shoshan S.H. Admon A.: novel technologies for cancer biomarker discovery: humoral proteomics. Cancer Biomark 3 (2007) 141-152
6. Caron M., and Choquet-Kastylevsky G. Joubert-Caron R.: cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 6 (2007) 1115-1122
7. Imafuku Y., and Omenn G.S. Hanash S.: proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers 20 (2004) 149-153
8. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Pfreundschuh M.: human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92 (1995) 11810-11813
9. Krause P., Türeci O., Micke P., Buhl R., and Huber C. Sahin U.: SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods 283 (2003) 261-267
10. Chen Y.T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94 (1997) 1914-1918
11. Tureci O., Mack U., Luxemburger U., Heinen H., Krummenauer F., Sester M., et al. Sahin U.: humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236 (2006) 64-71
12. Fossa A., Berner A., Fossa S.D., Hernes E., and Gaudernack G. Smeland E.B.: NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59 (2004) 440-447
13. Maio M., Coral S., Sigalotti L., Elisei R., Romei C., Rossi G., et al. Vitale M.: analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88 (2003) 748-754
14. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., et al. Old L.J.: a survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187 (1998) 1349-1354
15. Park S., Lim Y., Lee D., Cho B., Bang Y.J., Sung S., et al. Jeoung D.I.: identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 1625 (2003) 173-182
16. Di Modugno F., Bronzi G., Scanlan M.J., Del Bello D., Cascioli S., Venturo I., et al. Human Mena protein, a SEREX-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 109 (2004) 909-918
17. Jager D., Stockert E., Scanlan M.J., Gure A.O., Jager E., Knuth A., et al. Chen Y.T.: cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 59 (1999) 6197-6204
18. Pallasch C.P., Struss A.K., Munnia A., Konig J., Steudel W.I., and Fischer U. Meese E.: autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 117 (2005) 456-459
19. Kim M.S., Choi H.Y., Choi Y.S., and Kim J. Kim Y.-S.: optimized serological isolation of lung-cancer-associated antigens from a yeast surface-expressed cDNA library. J Microbiol Biotechnol 17 (2007) 993-1001
20. Wadle A., Mischo A., Imig J., Wüllner B., Hensel D., Wätzig K., et al. Renner C.: serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer 117 (2005) 104-113
21. Boder E.T. Wittrup K.D.: yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15 (1997) 553-557
22. Klade C.S., Voss T., Krystek E., Ahorn H., Zatloukal K., and Pummer K. Adolf G.R.: identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1 (2001) 890-898
23. Hong S.H., Misek D.E., Wang H., Puravs E., Giordano T.J., Greenson J.K., et al. Hanash S.M.: an autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64 (2004) 5504-5510
24. Fujita Y., Nakanishi T., Hiramatsu M., Mabuchi H., Miyamoto Y., Miyamoto A., et al. Tanigawa N.: proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 12 (2006) 6415-6420
25. Yang F., Xiao Z.Q., Zhang X.Z., Li C., Zhang P.F., Li M.Y., et al. Chen Z.C.: identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 6 (2007) 751-758
26. Le Naour F., Misek D.E., Krause M.C., Deneux L., Giordano T.J., and Scholl S. Hanash S.M.: proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7 (2001) 3328-3335
27. Desmetz C., Bibeau F., Boissie?re F., Bellet V., Rouanet P., Maudelonde T., et al. Solassol J.: proteomics-based Identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res 7 (2008) 3830-3837
28. Desmetz C., Bascoul-Mollevi C., Rochaix P., Lamy P.J., Kramar A., Rouanet P., Maudelonde T., Mangé A. and Solassol J.: identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009 in press.
29. Marouga R., and David S. Hawkins E.: the development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382 (2005) 669-678
30. Feng Y., Ke X., Ma R., Chen Y., and Hu G. Liu F.: parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 50 (2004) 416-422
31. Mattoon D., Michaud G., and Merkel J. Schweitzer B.: biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling. Expert Rev Proteomics 2 (2005) 879-889
32. Hudson M.E., Pozdnyakova I., Haines K., and Mor G. Snyder M.: identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 104 (2007) 17494-17499
33. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Chinnaiyan A.M.: autoantibody signatures in prostate cancer. N Engl J Med 353 (2005) 1224-1235
34. Qiu J., Madoz-Gurpide J., Misek D.E., Kuick R., Brenner D.E., Michailidis G., et al. Hanash S.: development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 3 (2004) 261-267
35. Nam M.J., Madoz-Gurpide J., Wang H., Lescure P., Schmalbach C.E., Zhao R., et al. Hanash S.M.: molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 3 (2003) 2108-2115
36. Ehrlich J.R., and Qin S. Liu B.C.: The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 1 (2006) 452-460
37. Qin S., Qiu W., Ehrlich J.R., Ferdinand A.S., Richie J.P., O'Leary M.P., et al. Liu B.C.: development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6 (2006) 3199-3209
38. Miller J.C., Zhou H., Kwekel J., Cavallo R., Burke J., Butler E.B., et al. Haab B.B.: antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3 (2003) 56-63
39. Kijanka G., and Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics (2009)
40. Chapman C., Murray A., Chakrabarti J., Thorpe A., Woolston C., Sahin U., et al. Robertson J.: autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18 (2007) 868-873
41. Koziol J.A., Zhang J.Y., Casiano C.A., Peng X.X., Shi F.D., Feng A.C., et al. Tan E.M.: recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9 (2003) 5120-5126
42. Zhong L., Peng X., Hidalgo G.E., Doherty D.E., and Stromberg A.J. Hirschowitz E.A.: identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 4 (2004) 1216-1225
43. Chapman C.J., Murray A., McElveen J.E., Sahin U., Luxemburger U., Türeci O., et al. Robertson J.F.: autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63 (2008) 228-233